Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19Lymphoid 12Myeloid 10Plasma cell 9Classical hematology 5Sarcoma 2CNS 2Other neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Wilms Tumor 1Sarcoma 1Neuroblastoma 1Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematopoietic Stem Cell Transplantation × Genitourinary × Clear all
NCT00405327 2017-11-06

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

University of Michigan Rogel Cancer Center

Phase 2 Completed
16 enrolled
CNSGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡